Hemodynamic effects of finerenone on blood pressure and heart rate in hospitalized patients with type 2 diabetes: a real-world study - Scorecard - MDSpire
Advertisement
Hemodynamic effects of finerenone on blood pressure and heart rate in hospitalized patients with type 2 diabetes: a real-world study
Clinical Scorecard: Acute Hemodynamic Impact of Finerenone on Blood Pressure and Heart Rate in Hospitalized Individuals with Type 2 Diabetes: A Real-World Analysis
At a Glance
Category
Detail
Condition
Type 2 Diabetes
Key Mechanisms
Finerenone acts as a selective mineralocorticoid receptor antagonist, reducing blood pressure and stabilizing heart rate.
Target Population
Hospitalized patients with Type 2 Diabetes and high urinary albumin-to-creatinine ratio.
Care Setting
Real-world clinical practice
Key Highlights
Finerenone was associated with significant reductions in both systolic and diastolic blood pressure within the first 24-48 hours.
Heart rate remained stable during the initial days of finerenone therapy.
Patients had notably high urinary albumin-to-creatinine ratios, indicating targeted use for high-risk kidney patients.
The distribution of background antihypertensive medications remained consistent during treatment.
Finerenone's acute effects were observed despite concurrent intensive therapies.
Guideline-Based Recommendations
Diagnosis
Monitor urinary albumin-to-creatinine ratio in patients with Type 2 Diabetes.
Management
Initiate finerenone in hospitalized patients with Type 2 Diabetes and high albuminuria.
Monitoring & Follow-up
Regularly assess blood pressure and heart rate during the first week of finerenone therapy.
Risks
Monitor for potential hyperkalemia, particularly in patients with impaired renal function.
Patient & Prescribing Data
Hospitalized individuals with Type 2 Diabetes and diabetic kidney disease.
Finerenone provides antihypertensive effects while maintaining heart rate stability.
Clinical Best Practices
Assess baseline hemodynamic parameters before initiating finerenone.
Continue monitoring renal function and potassium levels during treatment.
